Literature DB >> 26359499

Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).

Xiaoshan Min1, Daniela Ungureanu2, Sarah Maxwell3, Henrik Hammarén4, Steve Thibault1, Ellin-Kristina Hillert2, Merrill Ayres1, Brad Greenfield3, John Eksterowicz1, Chris Gabel3, Nigel Walker1, Olli Silvennoinen5, Zhulun Wang6.   

Abstract

JAK (Janus family of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling through cytokine receptors involved in immune responses and inflammation. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). The majority of disease-associated mutations in JAKs map to JH2, demonstrating its central regulatory function. JH2s were considered catalytically inactive, but JAK2 JH2 was found to have low autoregulatory catalytic activity. Whether the other JAK JH2s share ATP binding and enzymatic activity has been unclear. Here we report the crystal structure of TYK2 JH2 in complex with adenosine 5'-O-(thiotriphosphate) (ATP-γS) and characterize its nucleotide binding by biochemical and biophysical methods. TYK2 JH2 did not show phosphotransfer activity, but it binds ATP and the nucleotide binding stabilizes the protein without inducing major conformational changes. Mutation of the JH2 ATP-binding pocket increased basal TYK2 phosphorylation and downstream signaling. The overall structural characteristics of TYK2 JH2 resemble JAK2 JH2, but distinct stabilizing molecular interactions around helix αAL in the activation loop provide a structural basis for differences in substrate access and catalytic activities among JAK family JH2s. The structural and biochemical data suggest that ATP binding is functionally important for both TYK2 and JAK2 JH2s, whereas the regulatory phosphorylation appears to be a unique property of JAK2. Finally, the co-crystal structure of TYK2 JH2 complexed with a small molecule inhibitor demonstrates that JH2 is accessible to ATP-competitive compounds, which offers novel approaches for targeting cytokine signaling as well as potential therapeutic applications.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ATP binding; JAK tyrosine kinase; Janus kinase (JAK); TYK2; X-ray crystallography; crystal structure; protein kinase; pseudokinase domain; structural biology; structure-function

Mesh:

Substances:

Year:  2015        PMID: 26359499      PMCID: PMC4646372          DOI: 10.1074/jbc.M115.672048

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Authors:  Pipsa Saharinen; Mauno Vihinen; Olli Silvennoinen
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

2.  Conserved spatial patterns across the protein kinase family.

Authors:  Lynn F Ten Eyck; Susan S Taylor; Alexandr P Kornev
Journal:  Biochim Biophys Acta       Date:  2007-11-17

3.  Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1.

Authors:  M F Richter; G Duménil; G Uzé; M Fellous; S Pellegrini
Journal:  J Biol Chem       Date:  1998-09-18       Impact factor: 5.157

4.  Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.

Authors:  John S Tokarski; Adriana Zupa-Fernandez; Jeffrey A Tredup; Kristen Pike; ChiehYing Chang; Dianlin Xie; Lihong Cheng; Donna Pedicord; Jodi Muckelbauer; Stephen R Johnson; Sophie Wu; Suzanne C Edavettal; Yang Hong; Mark R Witmer; Lisa L Elkin; Yuval Blat; William J Pitts; David S Weinstein; James R Burke
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

5.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Authors:  Takaomi Sanda; Jeffrey W Tyner; Alejandro Gutierrez; Vu N Ngo; Jason Glover; Bill H Chang; Arla Yost; Wenxue Ma; Angela G Fleischman; Wenjun Zhou; Yandan Yang; Maria Kleppe; Yebin Ahn; Jessica Tatarek; Michelle A Kelliher; Donna S Neuberg; Ross L Levine; Richard Moriggl; Mathias Müller; Nathanael S Gray; Catriona H M Jamieson; Andrew P Weng; Louis M Staudt; Brian J Druker; A Thomas Look
Journal:  Cancer Discov       Date:  2013-03-07       Impact factor: 39.397

6.  Absence of cytokine receptor-dependent specificity in red blood cell differentiation in vivo.

Authors:  M A Goldsmith; A Mikami; Y You; K D Liu; L Thomas; P Pharr; G D Longmore
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

7.  Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.

Authors:  Yibing Shan; Kavitha Gnanasambandan; Daniela Ungureanu; Eric T Kim; Henrik Hammarén; Kazuo Yamashita; Olli Silvennoinen; David E Shaw; Stevan R Hubbard
Journal:  Nat Struct Mol Biol       Date:  2014-06-11       Impact factor: 15.369

Review 8.  Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity.

Authors:  Birgit Strobl; Dagmar Stoiber; Veronika Sexl; Mathias Mueller
Journal:  Front Biosci (Landmark Ed)       Date:  2011-06-01

Review 9.  Pseudokinases-remnants of evolution or key allosteric regulators?

Authors:  Elton Zeqiraj; Daan M F van Aalten
Journal:  Curr Opin Struct Biol       Date:  2010-11-10       Impact factor: 6.809

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  17 in total

Review 1.  The molecular details of cytokine signaling via the JAK/STAT pathway.

Authors:  Rhiannon Morris; Nadia J Kershaw; Jeffrey J Babon
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

2.  Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.

Authors:  Chunjian Liu; James Lin; Ryan Moslin; John S Tokarski; Jodi Muckelbauer; ChiehYing Chang; Jeffrey Tredup; Dianlin Xie; Hyunsoo Park; Peng Li; Dauh-Rurng Wu; Joann Strnad; Adriana Zupa-Fernandez; Lihong Cheng; Charu Chaudhry; Jing Chen; Cliff Chen; Huadong Sun; Paul Elzinga; Celia D'arienzo; Kathleen Gillooly; Tracy L Taylor; Kim W McIntyre; Luisa Salter-Cid; Louis J Lombardo; Percy H Carter; Nelly Aranibar; James R Burke; David S Weinstein
Journal:  ACS Med Chem Lett       Date:  2019-02-21       Impact factor: 4.345

3.  Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.

Authors:  David E Puleo; Kaury Kucera; Henrik M Hammarén; Daniela Ungureanu; Ana S Newton; Olli Silvennoinen; William L Jorgensen; Joseph Schlessinger
Journal:  ACS Med Chem Lett       Date:  2017-05-17       Impact factor: 4.345

4.  The N-Terminal GTPase Domain of p190RhoGAP Proteins Is a PseudoGTPase.

Authors:  Amy L Stiegler; Titus J Boggon
Journal:  Structure       Date:  2018-08-30       Impact factor: 5.006

5.  Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors.

Authors:  Christopher J Matheson; Kimberly A Casalvieri; Donald S Backos; Mohammed Minhajuddin; Craig T Jordan; Philip Reigan
Journal:  Eur J Med Chem       Date:  2020-04-16       Impact factor: 6.514

6.  Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling.

Authors:  R Moslin; D Gardner; J Santella; Y Zhang; J V Duncia; C Liu; J Lin; J S Tokarski; J Strnad; D Pedicord; J Chen; Y Blat; A Zupa-Fernandez; L Cheng; H Sun; C Chaudhry; C Huang; C D'Arienzo; J S Sack; J K Muckelbauer; C Chang; J Tredup; D Xie; N Aranibar; J R Burke; P H Carter; D S Weinstein
Journal:  Medchemcomm       Date:  2016-12-15       Impact factor: 3.597

Review 7.  Nucleotide-binding mechanisms in pseudokinases.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Olli Silvennoinen
Journal:  Biosci Rep       Date:  2015-11-20       Impact factor: 3.840

Review 8.  Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase.

Authors:  Stevan R Hubbard
Journal:  Front Endocrinol (Lausanne)       Date:  2018-01-05       Impact factor: 5.555

9.  Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction.

Authors:  Chun-Shan Liu; Hsin-Fang Yang-Yen; Ching-Shu Suen; Ming-Jing Hwang; Jeffrey Jong-Young Yen
Journal:  Sci Rep       Date:  2017-07-04       Impact factor: 4.379

10.  Structure of Fam20A reveals a pseudokinase featuring a unique disulfide pattern and inverted ATP-binding.

Authors:  Jixin Cui; Qinyu Zhu; Hui Zhang; Michael A Cianfrocco; Andres E Leschziner; Jack E Dixon; Junyu Xiao
Journal:  Elife       Date:  2017-04-22       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.